The TOC (Translocon at the Outer envelope of Chloroplasts)-TIC (Translocon at the Inner envelope of Chloroplasts) ...
When active filaments are exposed to localized illumination, they accumulate into stable structures along the boundaries of ...
Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 ...
Google DeepMind releases AlphaFold 3's source code to academics, marking a significant advance in AI-powered molecular biology and drug discovery, while balancing open science with commercial ...
A couple of months ago, our blog published an article on the exploding ubiquity of Trifluoroacetic acid (TFA) in the environment. TFA is a ...
The firm thinks Q3 was validating for its view of a slowing GA market and that Syfovre estimates need to be reset. Wells believes incrementally negative commentary on pricing and more gradual ramp ...
The pharmaceutical company's two main products, Syfovre and Empaveli, did not meet sales projections. Syfovre generated $152 million, falling short by $15.7 million, while Empaveli brought in $24.6 ...
They include very small molecules, such as urea, and complex structures, such as Taxol. As they may only be isolable in small quantities, have interesting biological activity and chemical ...
That approval set up a market clash with Apellis Pharma's complement C3 inhibitor Syfovre (pegcetacoplan), which was cleared a few months earlier. There are currently no approved treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback